Skip to content

Study · Animal study (in vivo) · rat · 2014

3 results

The opposing effects of ghrelin on hypothalamic and systemic inflammatory processes are modulated by its acylation status and food intake in male rats.

García-Cáceres C, Fuente-Martín E, Díaz F, Granado M, Argente-Arizón P, Frago LM, Freire-Regatillo A, Barrios V, Argente J, Chowen JA

Endocrinology21 May 2014Cited by 23 (Europe PMC)

PMID24848869 (opens in a new tab)DOI10.1210/en.2014-1074 (opens in a new tab)PepBankPUB-24848869
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In adult male Wistar rats, GHRP‑6 stimulated hypothalamic insulin-like growth factor I production.

    In plain wordsIn rats, GHRP‑6 increased hypothalamic insulin-like growth factor I production compared with saline.

    Peptide
    GHRP-6
    Outcome
    IncreaseHypothalamic insulin-like growth factor I production
    Study

    ratn: not reported in source

    adult male Wistar rats
    Comparator
    saline
    Outcome group
    Growth hormone and IGF-1 · Nervous system and cognition
    Studied dose
    5 μg/day · intracerebroventricular · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    AG, DAG, and GHRP-6 stimulated production of hypothalamic insulin like-growth factor I that is involved in cell protective mechanisms.
    1 context sentence
    Summary · context
    Adult male Wistar rats were treated icv (5 μg/day) with AG, DAG, the ghrelin mimetic GH-releasing peptide (GHRP)-6, AG, and pair-fed with controls (AG-pf) or saline for 14 days.
  2. 02AnimalAnimal study (in vivo)Safety outcome

    In adult male Wistar rats, no treatment, including GHRP‑6, produced observed gliosis.

    In plain wordsIn rats, researchers observed no gliosis after any treatment, including GHRP‑6.

    Peptide
    GHRP-6
    Outcome
    Direction not reportedGliosis
    Study

    ratn: not reported in source

    adult male Wistar rats
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    5 μg/day · intracerebroventricular · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    Gliosis was not observed in response to any treatment as glial markers were either reduced or unaffected.
    1 context sentence
    Summary · context
    Adult male Wistar rats were treated icv (5 μg/day) with AG, DAG, the ghrelin mimetic GH-releasing peptide (GHRP)-6, AG, and pair-fed with controls (AG-pf) or saline for 14 days.

Studies that did not test the peptide alone1

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 03AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism

    In adult male Wistar rats, glial markers were reduced or unchanged across treatments including GHRP‑6, without a separate GHRP‑6 estimate.

    In plain wordsIn rats, glial markers decreased or stayed unchanged across treatments including GHRP‑6.

    Peptide
    GHRP-6
    Outcome
    MixedGlial markers
    Study

    ratn: not reported in source

    adult male Wistar rats
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Gliosis was not observed in response to any treatment as glial markers were either reduced or unaffected.
    1 context sentence
    Summary · context
    Adult male Wistar rats were treated icv (5 μg/day) with AG, DAG, the ghrelin mimetic GH-releasing peptide (GHRP)-6, AG, and pair-fed with controls (AG-pf) or saline for 14 days.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.